CClinicalTrials.gg
Sign In
CompletedNCT06984926Updated Mar 19, 2026

A Study to Test How Well Multiple Doses of BI 3810477 Are Tolerated by Healthy Adults

A Phase 1 interventional study of BI 3810477 and Placebo in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Belgium. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The main objectives of this trial are to investigate safety, tolerability, and pharmacokinetics of BI 3810477 in healthy male and female trial participants when given as multiple rising doses.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,245 studies on the registry; 58 are open to participants now.

Of its 162 completed or terminated interventional studies of FDA-regulated products, 116 (72%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy male and female participants according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR), respiratory rate (RR), temperature), 12-lead electrocardiogram (ECG), and clinical laboratory tests.
  • Age of 18 to 60 years (inclusive, to be checked at time of signing informed consent).
  • BMI of 18.5 to 29.9 kg/m2 (inclusive).
  • Signed and dated written informed consent in accordance with international conference on harmonization-good clinical practice (ICH-GCP) and local legislation prior to admission to the trial.
  • Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Any finding in the medical examination (including BP, PR, RR, temperature or ECG) deviating from normal and assessed as clinically relevant by the investigator.
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimetre of mercury (mmHg), diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 100 beats per minute (bpm).
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance.
  • Any evidence of a concomitant disease assessed as clinically relevant by the investigator.
  • Further exclusion criteria apply.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    BI 3810477_dose group 1

    Drug: BI 3810477

  • Experimental
    BI 3810477_dose group 2

    Drug: BI 3810477

  • Experimental
    BI 3810477_dose group 3

    Drug: BI 3810477

  • Experimental
    BI 3810477_dose group 4

    Drug: BI 3810477

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugBI 3810477

    BI 3810477

  • DrugPlacebo

    Placebo for BI 3810477

06

What researchers measure

Primary outcomes

  1. Occurrence of any treatment-emergent adverse events assessed as drug-related by the investigator

    Time frame: Up to Day 117

Secondary outcomes

  1. Area under the concentration-time curve of BI 3810477 in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)

    Time frame: Up to Day 117

  2. Maximum measured concentration of BI 3810477 in plasma at steady state (Cmax,ss)

    Time frame: Up to Day 117

07

Study locations

1 site
  • SGS Life Science Services - Clinical Research
    Edegem, 2650, Belgium
08

References and documents

Related links

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06984926
Lead sponsor
Boehringer Ingelheim
Responsible party
Sponsor
First posted
May 22, 2025
Start date
Jun 6, 2025
Primary completion
Mar 9, 2026
Completion
Mar 9, 2026
Last update
Mar 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Boehringer Ingelheim

Start the discussion